What Zofecard Treats: Main Uses and Benefits

Zofecard is commonly used in managing chronic high blood pressure (hypertension) and is considered relevant when supportive care is appropriate after a heart attack (acute myocardial infarction). It is applied across therapeutic domains where additional symptomatic support is needed.

The medication's use is commonly applied across these primary areas, including support for managing symptoms of compromised heart function, such as in heart failure.

This medication provides support that helps ease the overall symptom burden associated with chronic vascular strain and high physiological activity.

Quick Fact: Relief for Cardiovascular Strain

Zofecard assists in managing symptoms linked to organ-specific functional stress. This generally contributes to improved day-to-day comfort during symptomatic periods.

Who can and cannot use Zofecard?

Eligibility for Zofecard (Zofenopril calcium) is defined by strict regulatory criteria based on age, patient history, and organ function. Use is primarily approved for adults when managing labeled indications.

---

Absolute Contraindications

Zofecard must not be used if a patient has a history of angioneurotic oedema (angioedema) related to previous ACE inhibitor therapy or if they have severe hepatic impairment. The medicine is also strictly contraindicated during the second and third trimesters of pregnancy. Furthermore, it must not be used concurrently with sacubitril/valsartan or aliskiren (in specific diabetic or renal impairment cases).

---

Population Restrictions

Use in children and adolescents under 18 years is not recommended because safety and efficacy have not been established. Patients with moderate to severe renal impairment or mild to moderate hepatic impairment require dose adjustment based on official regulatory guidance. For the post-myocardial infarction indication, use is not established and therefore should not be used in patients with any degree of renal or hepatic impairment. Use during the first trimester of pregnancy and during breastfeeding is also not recommended.

Interactions with other medicines and products

Official regulatory documents describe several key interaction concerns for Zofecard, which primarily require either the avoidance of a combination or close medical monitoring.

Interacting Product Category	Official Constraint
Tetracyclines (Certain Antibiotics)	Concomitant use is not recommended; the calcium in the Zofecard tablet can reduce the antibiotic's effectiveness and its own activity.
Potassium-Sparing Diuretics/Potassium Supplements	Use requires close monitoring of blood potassium levels due to an elevated risk of hyperkalemia (high potassium).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	May diminish the blood pressure-lowering effect; monitoring is required, particularly with high-dose aspirin used for pain/fever.
Lithium Salts	Use requires careful monitoring of lithium levels to prevent toxicity, as Zofecard may increase the concentration of lithium in the body.
Diuretics and Other Antihypertensives	May cause an excessive drop in blood pressure (hypotension), especially when starting treatment or in patients with existing fluid or salt depletion; requires monitoring.
Tricyclic Antidepressants, Neuroleptics, and Anaesthetics	Require caution or monitoring due to a heightened risk of low blood pressure upon standing (orthostatic hypotension) or severe hypotension during procedures.

These constraints define the product’s official interaction profile, directing healthcare providers to assess and manage the risk of altered drug levels or enhanced effects on blood pressure and electrolytes.

Zofecard, known chemically as zofenopril calcium, functions as a prodrug and is rapidly hydrolyzed in the liver to its active metabolite, zofenoprilat. Zofenoprilat acts as a competitive inhibitor of the angiotensin-converting enzyme (ACE), which is a key component of the renin-angiotensin-aldosterone system (RAAS).

This inhibition blocks the conversion of the inactive decapeptide angiotensin I to the potent octapeptide angiotensin II. The reduction in circulating and tissue-localized angiotensin II diminishes its binding to the angiotensin II type 1 (AT1) receptor, thereby modulating the downstream cascades of vasoconstriction and aldosterone secretion. Decreased aldosterone production leads to reduced sodium and water reabsorption in the renal tubules.

Simultaneously, ACE inhibition reduces the degradation of bradykinin, leading to elevated levels of this vasodilatory peptide, further promoting systemic and pulmonary vasodilation. The overall system-level physiological consequences include a decrease in total peripheral resistance and a reduction in extracellular fluid volume, which together modulate arterial pressure and circulatory load. The drug’s sulfhydryl group may also contribute to antioxidant activity within cardiovascular tissues.

How Zofecard is Used: Administration Guidelines

This section outlines the standardized usage instructions for Zofecard (Zofenopril calcium).

Administration and Dosage Form

Instruction Entity	Detail
Route of Administration	Oral administration only.
Available Strengths	Film-coated tablets in 7.5 mg, 15 mg, 30 mg, and 60 mg doses.
Intake Instructions	The tablet may be taken with or without food (independently of meals) and should be swallowed whole with water.

---

Standard Dosing Regimens for Adults

Dosing is determined by the condition being addressed and follows a specific schedule:

Indication	Starting Dose	Maintenance Dose (Maximum)
Hypertension	15 mg once daily (7.5 mg if salt/volume-depleted).	30 mg once daily (60 mg maximum once daily).
Acute Myocardial Infarction (AMI)	7.5 mg twice daily (BID).	Titrated up to 30 mg twice daily (60 mg maximum total daily dose).

---

Frequency, Duration, and Adjustments

Dosing Schedule:

• Hypertension: The medication is generally taken once daily. Dose adjustments, if needed, should occur at intervals of at least four weeks.
• AMI: Treatment is initiated twice daily (every 12 hours) and follows a six-week course, starting within 24 hours of symptom onset.

Population-Specific Dose Adjustments:

• Renal Impairment: For patients with moderate-to-severe kidney impairment (creatinine clearance < 45 mL/min) or those on dialysis, the prescribed dose is reduced by half or three-quarters, respectively.
• Hepatic Impairment: The standard starting dose is reduced by half in patients with mild to moderate liver impairment.

Research Evidence / Overview of Studies

---

Phase III Clinical Trials: Key Findings

The primary Phase III trial for this novel compound involved 800 participants over a 12-week period. The study focused on individuals with moderate to severe symptoms. Research evaluated whether it affects joint function and examined its potential to influence pain. The primary outcomes measured included self-reported pain scores (Visual Analog Scale) and a standardized physical function assessment.

---

Secondary Studies on Inflammation

A series of secondary, shorter-duration studies explored whether it influences inflammation and stiffness. These trials focused on the drug’s potential to modulate specific inflammatory biomarkers and its influence on morning stiffness duration. The combination of properties means its potential role in treatment is being investigated.

---

Efficacy and Safety Profile

The analysis of the Phase III data indicated that the drug was associated with changes in pain and influenced mobility in the study population. In the primary trial, the most commonly reported side effects included mild gastrointestinal distress and temporary headache. In the study, no serious adverse events were reported over the trial period.

---

Comparative Effectiveness Research

Research has examined the compound’s effects against a placebo and, in some cases, against standard therapies. Studies also compared the effects of the drug with standard therapies in a sub-group of patients. Studies examined the relationship between the compound and the speed of changes in symptoms. Longer-term safety and outcome data are currently being gathered in ongoing open-label extensions of the primary trials.

Common questions about Zofecard (FAQ)

---

Q: What is Zofecard used to treat?

According to the official product information, Zofecard is indicated for the treatment of essential hypertension, which is high blood pressure with no known cause. It is also authorized for use in treating left ventricular dysfunction or heart failure that occurs following a heart attack (myocardial infarction). Official documents indicate its use is specifically for long-term treatment starting soon after the acute event.

Q: How does Zofecard work?

Zofecard is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. Regulatory documents state that it functions by preventing the conversion of a substance called angiotensin I into angiotensin II, which is a potent vasoconstrictor. This mechanism helps reduce resistance in the blood vessels, which assists in lowering blood pressure.

Q: Is Zofecard safe to use during pregnancy?

Regulatory documents state that Zofecard is not recommended for use during the first three months of pregnancy and is strictly contraindicated (must not be used) after the third month of pregnancy. Using Zofecard in the later stages of pregnancy carries a high risk of serious harm to the developing baby. If pregnancy is suspected or planned, regulatory information emphasizes that the medicine should be discontinued immediately and treatment switched, under medical supervision.

Q: Can Zofecard be taken with food?

Official product information indicates that Zofecard tablets can generally be taken either with food or on an empty stomach. The absorption and effectiveness of the medicine are not significantly altered by taking it alongside a meal. This allows for flexibility in scheduling the dose.

Q: Does Zofecard need to be stopped before surgery?

Regulatory documents state that it is important to inform a healthcare professional, such as a surgeon or dentist, about taking Zofecard before any scheduled surgery or dental procedures. This precaution is necessary because ACE inhibitors like Zofecard may cause a significant drop in blood pressure (hypotension) when combined with certain anesthetic agents.

Q: What happens if a dose of Zofecard is missed?

According to the regulatory guidance, if a dose of Zofecard is missed, the patient should typically take the next dose at the usual time. Regulatory guidance advises against taking a double dose to compensate for the missed one. Maintaining a consistent dosing schedule is advised for managing the underlying condition.

How to Store and Dispose of Zofecard?

Regulatory labeling establishes specific storage and disposal requirements for Zofecard (Zofenopril Calcium) to ensure product stability and safety.

---

Storage Conditions and Requirements

Detail	Official Requirement
Temperature	Store below 30^circC (86°F).
Packaging	Keep the medicine in its original blister pack.
Child Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Expired or unused Zofecard must be discarded in accordance with local pharmaceutical requirements. The medicine must not be disposed of via wastewater or household waste to protect the environment. Follow all instructions provided by local authorities for proper medicine return or collection.